Mylan EpiPen Price Gouging Scandal
Market Context & Analysis
Starting Price: $43.00Mylan faces outrage after raising EpiPen price 500% to $600+ for 2-pack. Life-saving allergy treatment now unaffordable for many. CEO Heather Bresch testifies before Congress. Public anger at pharma pricing boils over. Generic competition eventually emerges.
Strong economy but healthcare costs major concern. Drug pricing becoming political crisis. Insurance coverage gaps leaving patients exposed.
Congressional hearings on drug pricing. Presidential election with both candidates attacking pharma prices. Public anger at pharmaceutical industry.
Mylan has effective EpiPen monopoly. Price increases gradually then dramatically over years. CEO compensation rising alongside prices. Generic version announced—effectively competing with self.
Pharmaceutical industry under intense scrutiny. Drug pricing reform threatened. Generic competition fear across sector. Mylan became poster child for pricing abuse.
- 500% price increase on life-saving drug
- Public outrage and political scrutiny intense
- CEO testimony before Congress
- Monopoly position exploited
- Generic competition eventually arrives
- Reputational damage significant
- Pricing power questioned across pharma